tbuckley/cabot-search huggingface dataset:
Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use–Associated Lung Injury Among Patients Treated at an Academic Medical Center
Authors: Scott K. Aberegg, Meghan M. Cirulis, Sean D. Maddock, Andrew Freeman, Lynn M. Keenan, Cheryl S. Pirozzi, Sanjeev M. Raman, Joyce Schroeder, Howard Mann, Sean J. Callahan
Journal: JAMA Network Open (2020)

<h3>Importance</h3> e-Cigarette, or vaping, product use–associated lung injury (EVALI) has caused more than 2800 illnesses and 68 deaths in the United States. Better characterization of this novel illness is needed to inform diagnosis and management. <h3>Objective</h3> To describe the clinical features, bronchoscopic findings, imaging patterns, and outcomes of EVALI. <h3>Design, Setting, and Participants</h3> This case series of 31 adult patients diagnosed with EVALI between June 24 and December 10, 2019, took place at an academic medical center in Salt Lake City, Utah. <h3>Exposures</h3> e-Cigarette use, also known as vaping. <h3>Main Outcomes and Measures</h3> Symptoms, laboratory findings, bronchoscopic results, imaging patterns, and clinical outcomes. <h3>Results</h3> Data from 31 patients (median [interquartile range] age, 24 [21-31] years) were included in the study. Patients were primarily men (24 [77%]) and White individuals (27 [87%]) who used e-cigarette products containing tetrahydrocannabinol (THC) (29 [94%]). Patients presented with respiratory (30 [97%]), constitutional (28 [90%]), and gastrointestinal (28 [90%]) symptoms. Serum inflammatory markers were elevated in all patients. Bronchoscopy was performed in 23 of 28 inpatients (82%) and bronchoalveolar lavage (BAL) revealed the presence of lipid-laden macrophages (LLMs) in 22 of 24 cases (91%). BAL samples tested positive for<i>Pneumocystis jirovecii</i>(3 patients [13%]), rhinovirus (2 patients [8%]), human metapneumovirus and<i>Aspergillus</i>(1 patient each [4%]); all except human metapneumovirus were determined to be false-positives or clinically inconsequential. The exclusive or dominant computed tomography (CT) pattern was organizing pneumonia in 23 of 26 cases (89%). Patients received antibiotics (26 [84%]) and corticosteroids (24 [77%]), and all survived; 20 patients (65%) seen in follow-up showed marked improvement, but residual symptoms (13 [65%]), radiographic opacities (8 [40%]), and abnormal pulmonary function tests (8 of 18 [44%]) were common. <h3>Conclusions and Relevance</h3> In this case series, patients with EVALI characteristically presented with a flu-like illness with elevated inflammatory markers, LLMs on BAL samples, and an organizing pneumonia pattern on CT imaging. Bronchoscopic testing for infection had a high incidence of false-positive results. Patients had substantial residual abnormal results at early follow-up. These data suggest a limited role for bronchoscopy in typical presentations of EVALI without risk factors for alternative diagnoses and the need for careful longitudinal follow-up.
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Authors: Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Michael C Jensen, Richard G Ellenbogen, Jean S Campbell, Robert H Pierce, Eric C Holland, Venu G Pillarisetty, Courtney A Crane
Journal: Journal for ImmunoTherapy of Cancer (2020)

Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the development of effective antitumor immune responses is hampered by restricted immune cell infiltration and an immunosuppressive tumor microenvironment (TME). An immunotherapy that infiltrates and persists in the solid TME, while providing local, stable levels of therapeutic to activate or reinvigorate antitumor immunity could overcome these challenges faced by current immunotherapies.Using lentivirus-driven engineering, we programmed human and murine macrophages to express therapeutic payloads, including Interleukin (IL)-12. In vitro coculture studies were used to evaluate the effect of genetically engineered macrophages (GEMs) secreting IL-12 on T cells and on the GEMs themselves. The effects of IL-12 GEMs on gene expression profiles within the TME and tumor burden were evaluated in syngeneic mouse models of glioblastoma and melanoma and in human tumor slices isolated from patients with advanced gastrointestinal malignancies.Here, we present a cellular immunotherapy platform using lentivirus-driven genetic engineering of human and mouse macrophages to constitutively express proteins, including secreted cytokines and full-length checkpoint antibodies, as well as cytoplasmic and surface proteins that overcomes these barriers. GEMs traffic to, persist in, and express lentiviral payloads in xenograft mouse models of glioblastoma, and express a non-signaling truncated CD19 surface protein for elimination. IL-12-secreting GEMs activated T cells and induced interferon-gamma (IFNγ) in vitro and slowed tumor growth resulting in extended survival in vivo. In a syngeneic glioblastoma model, IFNγ signaling cascades were also observed in mice treated with mouse bone-marrow-derived GEMs secreting murine IL-12. These findings were reproduced in ex vivo tumor slices comprised of intact MEs. In this setting, IL-12 GEMs induced tumor cell death, chemokines and IFNγ-stimulated genes and proteins.Our data demonstrate that GEMs can precisely deliver titratable doses of therapeutic proteins to the TME to improve safety, tissue penetrance, targeted delivery and pharmacokinetics.
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice
Authors: Paolo Sportoletti, Daniele Sorcini, Anna G. Guzman, Jaime M. Reyes, Arianna Stella, Andrea Marra, Sara Sartori, Lorenzo Brunetti, Roberta Rossi, Beatrice Del Papa, Francesco Maria Adamo, Giulia Pianigiani, Camilla Betti, Annarita Scialdone, Valerio Guarente, Giulio Spinozzi, Valentina Tini, Maria Paola Martelli, Margaret A. Goodell, Brunangelo Falini
Journal: Leukemia (2020)

Recurrent loss-of-function mutations of BCL6 co-repressor (BCOR) gene are found in about 4% of AML patients with normal karyotype and are associated with DNMT3a mutations and poor prognosis. Therefore, new anti-leukemia treatments and mouse models are needed for this combinatorial AML genotype. For this purpose, we first generated a Bcor-/- knockout mouse model characterized by impaired erythroid development (macrocytosis and anemia) and enhanced thrombopoiesis, which are both features of myelodysplasia/myeloproliferative neoplasms. We then created and characterized double Bcor-/-/Dnmt3a-/- knockout mice. Interestingly, these animals developed a fully penetrant acute erythroid leukemia (AEL) characterized by leukocytosis secondary to the expansion of blasts expressing c-Kit+ and the erythroid marker Ter119, macrocytic anemia and progressive reduction of the thrombocytosis associated with loss of Bcor alone. Transcriptomic analysis of double knockout bone marrow progenitors revealed that aberrant erythroid skewing was induced by epigenetic changes affecting specific transcriptional factors (GATA1-2) and cell-cycle regulators (Mdm2, Tp53). These findings prompted us to investigate the efficacy of demethylating agents in AEL, with significant impact on progressive leukemic burden and mice overall survival. Information gained from our model expands the knowledge on the biology of AEL and may help designing new rational treatments for patients suffering from this high-risk leukemia.
Consistency of variety of machine learning and statistical models in predicting clinical risks of individual patients: longitudinal cohort study using cardiovascular disease as exemplar
Authors: Yan Li, Matthew Sperrin, Darren M Ashcroft, Tjeerd Pieter van Staa
Journal: BMJ (2020)

To assess the consistency of machine learning and statistical techniques in predicting individual level and population level risks of cardiovascular disease and the effects of censoring on risk predictions.Longitudinal cohort study from 1 January 1998 to 31 December 2018.3.6 million patients from the Clinical Practice Research Datalink registered at 391 general practices in England with linked hospital admission and mortality records.Model performance including discrimination, calibration, and consistency of individual risk prediction for the same patients among models with comparable model performance. 19 different prediction techniques were applied, including 12 families of machine learning models (grid searched for best models), three Cox proportional hazards models (local fitted, QRISK3, and Framingham), three parametric survival models, and one logistic model.The various models had similar population level performance (C statistics of about 0.87 and similar calibration). However, the predictions for individual risks of cardiovascular disease varied widely between and within different types of machine learning and statistical models, especially in patients with higher risks. A patient with a risk of 9.5-10.5% predicted by QRISK3 had a risk of 2.9-9.2% in a random forest and 2.4-7.2% in a neural network. The differences in predicted risks between QRISK3 and a neural network ranged between -23.2% and 0.1% (95% range). Models that ignored censoring (that is, assumed censored patients to be event free) substantially underestimated risk of cardiovascular disease. Of the 223 815 patients with a cardiovascular disease risk above 7.5% with QRISK3, 57.8% would be reclassified below 7.5% when using another model.A variety of models predicted risks for the same patients very differently despite similar model performances. The logistic models and commonly used machine learning models should not be directly applied to the prediction of long term risks without considering censoring. Survival models that consider censoring and that are explainable, such as QRISK3, are preferable. The level of consistency within and between models should be routinely assessed before they are used for clinical decision making.
Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus
Authors: Nicoletta Di Maio, Giovanna Russo, Susanna Barella, Gian Luca Forni, Raffaella Colombatti, Lucia Notarangelo, Giovanna Graziadei, Antonella Sau, Luciana Rigoli, Piero Farruggia, Saveria Campisi, Tommaso Casini, Manuela Balocco, Gianluca Boscarol, Ilaria Capolsini, Paolo Grotto, Fiorina Giona, Ilaria Lazzareschi, Pellegrina Pugliese, Francesca Fioredda, Silvia Fasoli, Maria Caterina Putti, Maddalena Migliavacca, Corti Paola, Serena Tripodi, Paola Saracco, Simone Ferrero, Assunta Tornesello, Marilena Serra, Saverio Ladogana, Giovanni Palazzi, Federico Verzegnassi, Carlo Baronci, Giuseppe Palumbo, Simone Cesaro, Laura Sainati, Flavia Rivellini, Rosanna Di Concilio, Vania Munaretto, Elena Facchini, Paola Giordano, Maria Grazia Sanna, Silverio Perrotta, Maddalena Casale
Journal: Blood (2020)
Clinicopathological Description from the Largest Series of Patients with the Novel Pro106Leu <i>MPL</i> gene Mutation Associated with Hereditary Thrombocythemia
Authors: Musa Alzahrani, Areej Al Mugairi, Saeed Al Turki, Waleed Al Rajban, Fatimah Alshalati, Khadega A. Abuelgasim, Bader Alahmari, Thamer Al Bogami, Osama Ali, Fahad Almodaihsh, Maram Alotaibi, Aamer Aleem, Ahmed Alaskar
Journal: Blood (2020)
Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Authors: Yuqin Song, Wei Xu, Yongping Song, Lihong Liu, Song Lin, Zhiming Li, Ting Liu, Shuhua Yi, Daobin Zhou, Mingzhi Zhang, Yu Hu, Jie Jin, Huaqiang Zhu, Zhengguang Lu, Renbin Zhao, Zhixin Xu, Jun Zhu
Journal: Blood (2020)
V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
Authors: Tara Lin, Gabriel N. Mannis, Harry P. Erba, Mark Levis, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat
Journal: Blood (2020)
Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia
Authors: Leonardo R. Brandao, Igor Tartakovsky, Manuela Albisetti, Lisa Bomgaars, Elizabeth Chalmers, Lesley Mitchell, Matteo Luciani, Paola Saracco, Judy Felgenhauer, Olga Lvova, Monika Simetzberger, Zhichao Sun, Ingrid Gergei, Martina Brueckmann, Jacqueline Halton
Journal: Blood (2020)
TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
Authors: Catherine Lai, Jayakumar Vadakekolathu, Stephen Reeder, Sarah E. Church, Carmen Ballesteros-Merino, Ibrahim Aldoss, Anjali S Advani, John E. Godwin, Matthew J. Wieduwilt, Martha L. Arellano, Geoffrey L Uy, Farhad Ravandi, Matthew C Foster, Emmanuel Gyan, Patrick J. Stiff, Norbert Vey, Ashkan Emadi, Matteo Giovanni Carrabba, Roland B. Walter, Peter H. Sayre, Kathy Tran, Erin Timmeny, Michael P. Rettig, Patrick Kaminker, John Muth, Kuo Guo, Tung On Yau, Peter J.M. Valk, Bob Lowenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K Davidson-Moncada, Sergio Rutella
Journal: Blood (2020)
Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
Authors: Arata Ishii, Akira Yokota, Emiko Sakaida, Shokichi Tsukamoto, Katsuhiro Shono, Takashi Toya, Yuho Najima, Takeshi Kobayashi, Noriko Doki, Hideki Nakasone, Shinichi Kako, Takayoshi Tachibana, Masatsugu Tanaka, Nobuyuki Aotsuka, Toru Sakura, Shingo Yano, Shin Fujisawa, Yuki Shiko, Yohei Kawasaki, Chiaki Nakaseko, Yoshinobu Kanda
Journal: Blood (2020)
Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study
Authors: Zachary D. Epstein-Peterson, Sridevi Rajeeve, Andriy Derkach, Jae H. Park, Eytan M. Stein, Yanming Zhang, Harry J Iland, Martin S. Tallman
Journal: Blood (2020)
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
Authors: Meletios A Dimopoulos, Hang Quach, María-Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Maria Gavriatopoulou, Albert Oriol, Neil K Rabin, Ajay Nooka, Ming Qi, Bifeng Ding, Anita Zahlten-Kumeli, Saad Z. Usmani
Journal: Blood (2020)
Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy—Reply
Authors: Diane Thiboutot, Martina Cartwright, Alessandro Mazzetti
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis
Authors: Yazan Samhouri, Moaath Mustafa Ali, Thejus Jayakrishnan, Chelsea Peterson, Veli Bakalov, Salman Fazal, Cyrus Kahn, Rodney E Wegner, John Lister
Journal: Blood (2020)
Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
Authors: Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Ben-Yuan Jiang, Jin-Ji Yang, Qing Zhou, Chong-Rui Xu, Xiao-Rong Yang, Yi-Long Wu
Journal: Journal of Thoracic Oncology (2020)
Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes
Authors: Saurabh Zanwar, Jithma P. Abeykoon, Stephen M. Ansell, Morie A. Gertz, Jonas Paludo, Rebecca L. King, Rong He, Carrie A. Thompson, Rahma M Warsame, Grzegorz S. Nowakowski, David J. Inwards, Thomas E. Witzig, Martha Q. Lacy, Wilson I Gonsalves, Angela Dispenzieri, David Dingli, Ronald S. Go, Thomas M. Habermann, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar, Prashant Kapoor
Journal: Blood (2020)
Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology
Authors: Andrea J. Radtke, Arthur L. Shaffer, Stefania Pittaluga, Alexander Bagaev, Nishant Thakur, Theresa Davies-Hill, Olga Plotnikova, Ilia Galkin, Ekaterina Postovalova, Viktor Svekolkin, Sergei Isaev, Yaroslav Lozinsky, Mark Meerson, Arina Varlamova, Pavel Ovcharov, Margarita Polyakova, Krystle Nomie, Ekaterina Nuzhdina, Nikita Kotlov, Maria Tsiper, Felix Frenkel, Ravshan Attaulakhanov, Nathan H Fowler, Ziv Yaniv, Bradley C Lowekamp, Michael Kelly, Ezzat Dadkhah, Da Wei Huang, Jagan R. Muppidi, Elaine S. Jaffe, Wyndham H. Wilson, Louis M. Staudt, Ronald N. Germain, Mark Roschewski
Journal: Blood (2020)
Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)
Authors: Fabian Frontzek, Marita Ziepert, Maike Nickelsen, Bettina Altmann, Bertram Glass, Mathias Haenel, Lorenz Truemper, Gerhard Held, Martin Bentz, Peter Borchmann, Martin Dreyling, Andreas Viardot, Frank P. Kroschinsky, Bernd Metzner, Annette M. Staiger, Heike Horn, German Ott, Andreas Rosenwald, Markus Loeffler, Georg Lenz, Norbert Schmitz
Journal: Blood (2020)
Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes
Authors: Nicholas J. Short, Hagop M. Kantarjian, Keyur Patel, Steven M. Kornblau, Jeffrey L. Jorgensen, Sa A Wang, Marina Konopleva, Nitin Jain, Partow Kebriaei, Musa Yilmaz, Ghayas C. Issa, Jairo A. Matthews, Munazza Noor, Rebecca Garris, Farhad Ravandi, Elias Jabbour
Journal: Blood (2020)
T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG
Authors: Jonathan Feld, Jane Houldsworth, Asha Reddy, Zinnia Mai, Shafinaz Hussein, Shyamala C. Navada, Lewis R. Silverman, Meenakshi Mehrotra
Journal: Blood (2020)
Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study
Authors: Rosalinda Termini, Evangelos Terpos, Albert Pérez, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, Fernando Solano Ramos, Sara Rodríguez, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, Marco Chiarini, Viviana Giustini, Jill Corre, Francois Vergez, Marc S. Raab, Niels Weinhold, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, Maria Elena Cabezudo, Valentin Cabañas, Enrique M. Ocio, Joaquin Martinez-Lopez, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, Roman Hajek, Heinz Ludwig, Hartmut Goldschmidt, Herve Avet-Loiseau, Aldo M. Roccaro, Jesús F. San-Miguel, Bruno Paiva
Journal: Blood (2020)
Hematopoietic Stem Cells Are Endowed with Erythroid Signature in Beta-Thalassemia
Authors: Maria Rosa Lidonnici, Giulia Chianella, Francesca Tiboni, Matteo Barcella, Ivan Merelli, Samantha Scaramuzza, Claudia Rossi, Stefania Crippa, Maria Ester Bernardo, Fabio Ciceri, Alessandro Aiuti, Sarah Marktel, Giuliana Ferrari
Journal: Blood (2020)
A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies
Authors: Martin G. Klatt, Zhiyuan Yang, Jianying Liu, Tatyana Korontsvit, Sung Soo Mun, Leila Peraro, Thomas J. Gardner, Christopher Bourne, Megan M. Dacek, Tao Dao, Cheng Liu, David A. Scheinberg
Journal: Blood (2020)
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Authors: Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin, Radwa Sharaf, Nora Sanchez, Ameet Guria, Max Minker, Gerald Li, Virginia Fisher, Ethan S. Sokol, Dean C. Pavlick, Jay A. Moore, Alan Braly, Gaurav Singal, David Fabrizio, Leah A. Comment, Naiyer A. Rizvi, Brian M. Alexander, Garrett M. Frampton, Priti S. Hegde, Lee A. Albacker
Journal: Cancer Discovery (2020)

Abstract Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH in oncogenesis and treatment, we utilized a pan-cancer genomic dataset of 83,644 patient samples, a small subset of which had treatment outcomes with immune checkpoint inhibitors (ICI). HLA-I LOH was common (17%) and unexpectedly had a nonlinear relationship with tumor mutational burden (TMB). HLA-I LOH was frequent at intermediate TMB, yet prevalence decreased above 30 mutations/megabase, suggesting highly mutated tumors require alternate immune evasion mechanisms. In ICI-treated patients with nonsquamous non–small cell lung cancer, HLA-I LOH was a significant negative predictor of overall survival. Survival prediction improved when combined with TMB, suggesting TMB with HLA-I LOH may better identify patients likely to benefit from ICIs. Significance: This work shows the pan-cancer landscape of HLA-I LOH, revealing an unexpected “Goldilocks” relationship between HLA-I LOH and TMB, and demonstrates HLA-I LOH as a significant negative predictor of outcomes after ICI treatment. These data informed a combined predictor of outcomes after ICI and have implications for tumor vaccine development. This article is highlighted in the In This Issue feature, p. 211
Human Placenta Derived Exosomes Enhance Ischemia Repair in a Mouse Model of Hind-Limb Ischemia
Authors: Qian Ye, Shuyang He, Joseph Gleason, Bhavani Stout, Navjot Shah, John Hariri, Chole Holland, Srinivas Somanchi, Xiaokui Zhang, Robert Hariri
Journal: Blood (2020)